Grand Pharmaceutical Group

Focusing on the two core areas of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment, the company has become a leading enterprise in China’s nuclear medicine anti-tumor diagnosis and treatment sector and has built a comprehensive cerebro-cardiovascular precision interventional diagnosis and treatment technology platform with internationally advanced capabilities.

Nuclear Medicine for Anti-Tumor Diagnosis and Treatment

Our radiopharmaceutical segment for anti-tumor diagnosis and therapy is one of the most globally integrated business areas within the Group. Centered on the concept of integrated cancer diagnosis and treatment, this segment currently has 15 globally innovative products in the R&D and registration stages, spanning 5 radioisotopes and targeting 7 types of cancer. At the early research stage, we have 12 Radioisotope Drug Conjugates (RDCs) under development. Covering both diagnostic and therapeutic applications, the portfolio provides multi-indication treatment options and comprehensive solutions that integrate diagnosis and therapy, delivering globally leading anti-cancer care. The flagship product, SIR-Spheres® Yttrium-90 [90Y] Microsphere Injection (Yigantai®), is the world’s first and currently the only FDA-approved Selective Internal Radiation Therapy (SIRT) product indicated for both unresectable hepatocellular carcinoma (HCC) and liver metastases from colorectal cancer. The product has been recommended by multiple international authoritative clinical guidelines and has also been incorporated into several leading Chinese clinical practice guidelines. Driven by our “Go Global” development strategy, we are the only international nuclear medicine company that delivers end-to-end capabilities spanning early research, clinical development, regulatory approval and commercialization, with a fully integrated global industrial chain covering R&D, manufacturing, distribution and sales. We are also the sole company by far with nuclear medicine production facilities spanning across key regions including China, the United States, Europe, and the Asia-Pacific, and operate a fully globalized sales network. With Boston and Chengdu as core R&D hubs and production capabilities deployed across Boston, Frankfurt, Singapore, and Chengdu, we have established a strong global supply network covering over 50 countries and regions. Our world-class radiopharmaceutical R&D and manufacturing base in Wenjiang, Chengdu, has obtained a Class A Radiation Safety License issued by China’s Ministry of Ecology and Environment. It is one of the most advanced smart factories worldwide, featuring the broadest radioisotope portfolio and the highest level of automation in the industry. The facility operates under an integrated model combining ligands, radioisotopes, technology platforms, and intelligent manufacturing, establishing a fully autonomous and controllable end-to-end system from target discovery to clinical application, with 100% in-house production. Supported by a globally leading full-process radiation monitoring system, the base achieves nuclear-power-grade safety standards and unmanned intelligent manufacturing, enabling zero radiation leakage, zero environmental discharge, and zero occupational exposure exceedance, meeting the highest international standards for nuclear facilities. This base further strengthens our industrial foundation, accelerates the global launch of innovative therapies, and supports high-quality development of the nuclear medicine sector, laying a solid foundation for the localization of radiopharmaceuticals and the creation of high-value blockbuster products.

Cerebro-Cardiovascular Precision Intervention Diagnosis and Treatment

Adhering to the therapeutic philosophy of “intervention without implantation,” the company has established a comprehensive layout across three key directions: access management, structural heart disease, and heart failure. Centered on the Boston R&D Center (USA), a precision interventional diagnosis and treatment platform with internationally leading standards has been built. With Boston, Wuhan, Changzhou, and Shanghai as core R&D hubs, and Boston, Wuhan, and Changzhou as core manufacturing bases, the company has formed a fully integrated industrial chain spanning R&D, regulatory registration, manufacturing, and commercialization. To date, the company has completed the full construction of both passive and active innovative medical device platforms, and has laid out multiple globally innovative products and China-first products. Among them, the Iberis™ multipolar renal artery radiofrequency ablation system is currently the only renal denervation (RDN) product worldwide that has obtained both EU CE certification and NMPA approval, while featuring dual access via radial and femoral arteries, enabling efficient treatment of diseases related to renal artery stenosis. NOVASIGHT & NOVASYNC represent the world’s first commercially available intravascular dual-modality imaging system, while Lava™, an innovative liquid embolic agent, is the first and only product approved by the U.S. FDA for the treatment of peripheral arterial bleeding. Looking ahead, the company is committed to building this segment into a leading precision interventional diagnosis and treatment platform for cerebro-cardiovascular diseases in China and globally.

Grand Pharma has cultivated deep expertise over many years in respiratory and critical care, ENT, and cerebro-cardiovascular fields. It owns multiple high-barrier products and exclusive varieties with leading market shares, supported by strong brand recognition and a solid market position, while maintaining a robust reserve of innovative products.

Respiratory and Critical Care

Adhering to an R&D philosophy that integrates independent innovation with global expansion, Grand Pharma has built a full-cycle product portfolio for chronic airway disease management and a comprehensive critical care pipeline, continuously consolidating its industry-leading position in this field. Its flagship product Qienuo® Eucalyptol, Limonene and Pinene Enteric Soft Capsules is a nationally exclusive, self-developed product and has ranked No.1 for many consecutive years in the hospital oral expectorant and antitussive market in China. Two globally innovative combination inhalation therapies for asthma—Atectura® and Enerzair®—represent a new generation of fixed-dose combination inhalers. In November 2025, the globally innovative combination nasal spray Ryaltris® introduced by Grand Pharma received marketing approval from the National Medical Products Administration (NMPA). This product, Ryaltris® (olopatadine hydrochloride and mometasone furoate nasal spray), is indicated for the treatment of moderate to severe allergic rhinitis.

Eye, Nose, and Throat (ENT)

In the ENT field, Grand Pharma follows a development strategy that integrates traditional Chinese and Western medicine and combines pharmaceuticals with medical devices, continuously strengthening its industry influence and achieving new breakthroughs across business areas. Its therapeutic coverage spans multiple specialties including ophthalmology, otolaryngology, and dentistry, encompassing chemical formulations, traditional Chinese medicines, and health products across prescription drugs, OTC products, medical devices, and consumer healthcare. Ophthalmology is one of Grand Pharma’s key strategic development directions. The company continues to focus on ophthalmic drug innovation and is among the companies with the most extensive ophthalmology innovation pipelines in China, covering traditional Chinese medicines, chemical drugs, OTC products, and medical devices. An integrated ophthalmology ecosystem combining treatment, diagnosis, and eye health care has been established. Its ophthalmic drug manufacturing base, EBE Pharmaceutical Co., Ltd., is the largest ophthalmic formulation production enterprise in China. Focusing on global ophthalmic drug innovation, Grand Pharma has achieved continuous breakthroughs in R&D and established a professional, full-series, multi-category innovative product system. Its pipeline includes multiple globally innovative products, such as the world’s first and only approved innovative treatment for dry eye disease—varenicline tartrate nasal spray (OC-01), the world’s first and only drug for Demodex blepharitis (TP-03), products for post-operative anti-inflammatory and analgesic ophthalmic therapy, the globally innovative pterygium treatment CBT-001, and products for myopia. The ophthalmology flagship product Ruizhu® (Polyvinyl Alcohol Eye Drops) ranks first in market share within the polyvinyl alcohol category for eye fatigue in China’s retail terminal market and remains among the top three in overall eye-fatigue treatment categories. Grand Pharma has also established a strong presence in traditional Chinese medicine and ethnic medicine. Its subsidiaries, Grand Beilin (Xi’an) Pharmaceutical Co., Ltd. and Grand Beilin (Qinghai) Pharmaceutical Co., Ltd., together hold more than 30 exclusive products. Xi’an Beilin’s flagship products include the Jinsang (Golden Throat) Series, Hexue Mingmu Tablets, and Maixuekang Capsules / Enteric-coated Tablets. Qinghai Beilin owns five Tibetan medicine products, including Danzhen Toutong Capsules, four of which are exclusive varieties.

Cardiovascular & Cerebrovascular Emergency Care

Focusing on both emergency rescue and chronic disease management, Grand Pharma has established a pipeline of more than 20 products under development. By combining independent innovation with breakthroughs in high-barrier generic technologies, the company continues to expand and develop urgently needed therapies for cardiovascular and cerebrovascular emergency care as well as chronic disease treatment. In the emergency care segment, Grand Pharma has been designated as a National Essential Medicines Manufacturing Base, an Emergency Medicines Manufacturing Base, and a National Centralized Production Base for Small-Volume and Shortage Drugs. The company has over 30 products in this field, including 14 products listed in China’s National Emergency & Critical Care Drug Catalogue and 16 products included in the National Shortage Drug Catalogue. Its product pipeline ranks among the leading positions in the industry, covering in-hospital emergency care, pre-hospital emergency care, and community emergency response, thereby addressing all major emergency care scenarios. The company has built a strong portfolio of leading products, including Hexinshuang® / Hebeishuang® (Diltiazem series), Anbuleke®, Limeitong® (Eplerenone Tablets), and Nengqilang® (Coenzyme Q10 Tablets), all of which continue to maintain strong market leadership. The innovative product Jext® pre-filled epinephrine auto-injector is designed for self-, family-, or community-based treatment of severe allergic reactions, filling a critical gap in China. In January 2023, it obtained approval under the Guangdong–Hong Kong–Macao Greater Bay Area policy for urgently needed imported Hong Kong and Macao drugs. Another global innovation, Neffy® epinephrine nasal spray, is the first non-injectable epinephrine product approved by the U.S. FDA in nearly 37 years for self-administration. It offers the advantages of ease of use, portability, and avoidance of injection pain and needle phobia, providing a new option for emergency allergy management.

Our API segment has developed a robust and diversified product pipeline with a strong cluster-based portfolio advantage, combining high-volume APIs with specialty APIs, supported by a global sales network. As a critical upstream component of our integrated API–formulation supply chain, we now operate multiple modern API manufacturing bases featuring advanced equipment, industry-leading processes, strong industrialization capabilities, and rigorous quality control systems. Focusing on five key therapeutic areas—cardiovascular & cerebrovascular, anti-infective, analgesic & antipyretic, gastrointestinal, and anticancer—we support the full lifecycle of drug product development and manufacturing within our pharmaceutical technology business. This ensures high standards and consistency in finished formulations, enabling true integration of upstream and downstream industrial advantages.

mRNA Technology

We focus on the development of mRNA therapeutics, particularly in oncology and anti-infective indications. We have successfully established both an mRNA production technology platform and a Lipid Nanoparticle (LNP) delivery technology platform. Our pipeline includes the therapeutic cancer vaccine ARC01 (A002), targeting HPV-16-positive solid tumors. In January 2024, ARC01 received approval in China to initiate Phase I clinical trials, making it the country's first mRNA therapeutic cancer vaccine approved for HPV-positive tumor trials.

We are a leading global supplier of high quality amino acids, committed to technological innovation and stringent quality assurance. We place strong emphasis on technological innovation and the development of a high-standard quality assurance system. We have obtained comprehensive domestic and international quality certifications and have been recognized with multiple national-level honors, including National Green Factory, National Manufacturing Single Champion Demonstration Enterprise, National Specialized and Innovative Enterprise, and National Intellectual Property Demonstration Enterprise.

Our biotechnology R&D team consists of over 90 researchers, with more than 200 invention patents granted. We have led or participated in the development of over 60 national, industrial, and association standards, nearly 50 of which have already been issued. We offer nearly 50 types of amino acids and derivatives, and possess 26 API registration certificates, the highest number in China for amino acid APIs. Our amino acid sales network covers 137 countries and regions worldwide. We have long served high-quality domestic and international clients, including Fortune Global 500 companies, and have established stable, long-term cooperative relationships across the upstream and downstream segments of the industrial chain. As a result, our global brand recognition and market reputation rank among the industry’s leading positions.